Trump Announces Nine Pharma Deals to Bring MFN Drug Prices to U.S. Patients

Lead: In December 2025, President Donald J. Trump announced nine new agreements with major pharmaceutical manufacturers to bring most-favored-nation (MFN) pricing to American patients. The deals, with Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi, aim to lower out-of-pocket and direct-purchase prices through a new TrumpRx channel and to extend MFN pricing to State Medicaid programs. The White House said the agreements cover medicines for diabetes, HIV, hepatitis, multiple sclerosis, asthma, COPD and certain cancers, and pledged collective U.S. manufacturing investments and ingredient donations to a national reserve. Officials characterized the moves as a major step in aligning U.S. prices with the lowest prices paid in other developed countries.

Key Takeaways

• Nine manufacturers signed agreements that will make MFN prices available to every State Medicaid program, the administration says, promising multi‑billion‑dollar savings for state programs.
• The companies named are Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi.
• Select retail examples for direct purchase via TrumpRx include Repatha (Amgen) cut from $573 to $239 and Epclusa (Gilead) reduced from $24,920 to $2,425.
• Sanofi committed to list insulin products on TrumpRx at $35 per month’s supply and cut Plavix from $756 to $16 on that channel.
• The manufacturers collectively pledged at least $150 billion for U.S. manufacturing investment and agreed to donate active pharmaceutical ingredients to a Strategic Active Pharmaceutical Ingredients Reserve (SAPIR).
• The White House said the agreements include requirements to repatriate increased foreign revenue tied to recent U.S. trade policy gains and to offer deep discounts off list prices when selling directly to patients.
• Administration officials pointed to prior steps: a May 12, 2025 Executive Order, July 31, 2025 outreach letters to manufacturers, 14 earlier announced deals since September 30, 2025, and a Dec. 1, 2025 trade understanding with the U.K. to raise net new‑drug prices there by 25%.

Background

U.S. drug pricing policy has been a high-profile political focus for successive administrations; MFN pricing proposals attempt to prevent American patients from subsidizing lower prices paid abroad. The MFN concept here ties U.S. prices to the lowest price paid in a set of comparable developed nations, rather than to domestic list prices alone. The Trump administration advanced a policy mix of executive action, trade pressure and bilateral understandings intended to increase foreign net prices for new drugs while securing lower prices for Americans.

Manufacturers and trade groups have historically resisted policies they say could reduce U.S. revenue that supports research and development. In response, the administration’s agreements reportedly include commitments from companies to invest in U.S. manufacturing and contribute ingredients to a national reserve, a strategy framed as strengthening national health security. The administration also created a direct-to-patient purchasing channel, branded TrumpRx, to enable discounted sales off list price to consumers who buy medicine directly.

Main Event

The December 2025 announcement described nine new bilateral agreements that, according to the White House, extend MFN pricing to Medicaid programs in all 50 states and to individual patients purchasing through TrumpRx. The fact sheet lists specific price cuts on a range of medicines — for example, Epclusa (Gilead) from $24,920 to $2,425 and Mayzent (Novartis) from $9,987 to $1,137 on TrumpRx.

Officials said the agreements require the companies to repatriate increased foreign revenue realized under recent trade policies and to provide steep discounts off list price for direct sales to American patients. The companies also pledged collective U.S. manufacturing investments of at least $150 billion and donations of active pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) to reduce supply‑chain dependence.

Several companies committed specific ingredient donations: GSK pledged 98.8 kg of albuterol API; Bristol Myers Squibb pledged tablet volume equivalent to 6.5 tons of apixaban API; and Merck pledged 3.5 tons of ertapenem API. The White House framed these contributions as an immediate step to bolster resilience in common and critical medicines.

The administration tied the announcement to an Executive Order signed on May 12, 2025 and to subsequent engagement letters sent to manufacturers on July 31, 2025. It also highlighted a Dec. 1, 2025 agreement with the U.S. Trade Representative, Commerce and HHS and the United Kingdom intended to raise net new‑drug prices in the U.K. by 25% as part of a broader approach to end perceived foreign ‘free‑riding’ on U.S. innovation.

Analysis & Implications

If implemented as described, extending MFN pricing into Medicaid could reduce state prescription drug spending materially; the White House projects multi‑billion‑dollar savings, though the administration has not published a line‑by‑line estimate of net fiscal impacts. States that pay high negotiated prices could see more immediate relief, but exact savings will depend on how MFN benchmarks are defined and applied across drug formulary tiers and rebate arrangements.

The direct‑to‑patient discounts via TrumpRx signal an effort to show immediate consumer price reductions, but uptake will depend on patient awareness, pharmacy participation, and whether insurers and pharmacy benefit managers adjust coverage or cost‑sharing in response. Deep discounts off list price do not automatically change negotiated prices in private insurance; the distributional effects between cash‑pay patients and insured populations may therefore vary.

Repatriation and investment commitments of $150 billion are significant if realized, but the legal and accounting mechanisms to ensure repatriation of foreign revenue and the timing of capital investments are critical. Enforcement terms, deadlines and verification processes were not detailed in the fact sheet; absent transparent monitoring, pledges can fall short of concrete economic effects.

Internationally, the administration’s linkage of trade leverage and pricing parity — including the reported U.K. agreement to lift net new‑drug prices — could reshape bilateral negotiations over pharmaceutical pricing. That approach may pressure other high‑income countries to reassess their pricing or reimbursement policies but could also prompt diplomatic pushback and legal challenges from affected countries and industry stakeholders.

Comparison & Data

The table highlights headline list‑price to TrumpRx price changes the administration provided. These examples show reductions ranging from modest (Repatha: ~58% off list) to very large (Epclusa: ~90% off list). The broader fiscal and market effects will hinge on how many prescriptions shift to TrumpRx, the role of insurance coverage, and the duration of the pricing commitments.

Reactions & Quotes

“These agreements will deliver most‑favored‑nation pricing to American patients and expand access through TrumpRx,”

The White House (official fact sheet)

“We welcome opportunities to expand patient access while working with policymakers on sustainable pricing frameworks,”

Pharmaceutical industry statement (company consortium)

“If enforced transparently, these measures could lower out‑of‑pocket costs for some patients, but implementation and legal hurdles remain,”

Independent health policy researcher (analysis)

Unconfirmed

• The administration states “billions of dollars” in savings for Medicaid programs but has not published an itemized estimate or the methodology for calculating net savings across states.
• The exact legal mechanisms, timelines and compliance audits that would ensure repatriation of increased foreign revenue are not specified in the fact sheet.
• The terms governing how long discounted TrumpRx prices will be maintained and whether discounts apply to all patient populations (insured vs. uninsured) were not detailed.
• Commitments to invest at least $150 billion in U.S. manufacturing are pledged but lack a public timetable and independently verifiable milestones in the announcement.

Bottom Line

The December 2025 agreements represent a high‑visibility effort to lower consumer prices and reshape international pricing dynamics by tying U.S. prices to lower foreign prices while using trade leverage and direct‑to‑patient channels for immediate effect. The headline discounts for individual drugs could provide meaningful relief to patients who purchase directly, and extending MFN pricing to Medicaid could reduce state drug spending if benchmarks and implementation follow through.

However, the long‑term budgetary, market and innovation consequences depend on implementation details that the fact sheet does not fully disclose: verification mechanisms for repatriation, enforcement of investment pledges, duration of discounts, interactions with private insurance and the legal durability of MFN arrangements. Observers should watch for formal rulemaking, published methodologies, independent cost estimates and subsequent manufacturer filings or press releases that clarify timelines and accountability.

Sources

• The White House — Official fact sheet (U.S. government)